• WZ4003: Precision NUAK1/2 Inhibitor Workflows for Cancer and

  2026-05-07

  WZ4003 is a highly selective NUAK1/2 inhibitor, enabling researchers to dissect cell migration, proliferation, and tau phosphorylation pathways with unprecedented specificity. This article offers detailed workflows, troubleshooting strategies, and practical protocol parameters, translating recent findings in cancer and neurodegeneration models into actionable laboratory guidance.

• KPT-330 (Selinexor): Translational Advances in Nuclear Expor

  2026-05-06

  Explore how KPT-330 (Selinexor) is reshaping cancer research as a selective CRM1 inhibitor. This article delivers a deep dive into mechanistic insights, protocol optimization, and the translational impact of recent breakthroughs, with a focus on practical assay decisions and unique research strategies.

• Quercetin (N1841): Mechanistic Insights as a PI3K Inhibitor

  2026-05-06

  Quercetin, a dietary flavonoid and PI3K inhibitor, demonstrates robust anti-inflammatory and antineoplastic effects in preclinical research. Its ability to modulate key intracellular signaling pathways and promote apoptosis underpins its widespread adoption in cancer and neuroinflammation studies.

• Myriocin as a Serine Palmitoyltransferase Inhibitor: Workflo

  2026-05-05

  Myriocin empowers researchers to dissect sphingolipid metabolism and cell cycle regulation with precision, thanks to its potent, selective inhibition of serine palmitoyltransferase. This guide translates cutting-edge findings and validated protocols into actionable steps for cancer, immunology, and cardiovascular research, with troubleshooting tips and data-backed optimization strategies.

• Nocodazole: Precision Microtubule Polymerization Inhibitor W

  2026-05-05

  Nocodazole stands out as a potent, reversible microtubule polymerization inhibitor, enabling high-resolution dissection of cell cycle regulation and microtubule dynamics. This guide details evidence-based protocols, advanced applications in translational research, and troubleshooting strategies for maximizing assay reproducibility and impact in cancer research.

• Trametinib (GSK1120212): Targeting B-RAF–MEK–ERK Axis in Pai

  2026-05-04

  Explore how Trametinib (GSK1120212) enables advanced modulation of the B-RAF–MEK–ERK pathway, extending its value beyond oncology into neural pain sensitization research. Unlock protocol strategies and mechanistic insights grounded in new primary literature.

• Trametinib (GSK1120212): Reliable MEK1/2 Inhibition in Cell

  2026-05-04

  This article addresses challenges in cell viability and proliferation assays by showcasing Trametinib (GSK1120212), SKU A3018, as a rigorously validated MEK1/2 inhibitor. Integrating recent evidence and best practices, we guide biomedical researchers on maximizing reproducibility and interpretability in MAPK/ERK pathway studies with high-quality reagents from APExBIO.

• PD 0332991 (Palbociclib) HCl: Rethinking CDK4/6 Inhibition

  2026-05-03

  This thought-leadership article for translational researchers explores the mechanistic foundation, strategic workflow guidance, and evolving research frontiers enabled by PD 0332991 (Palbociclib) HCl. We bridge rigorous evidence, including new gene-senescence links, with actionable protocols and a vision for next-generation cancer research.

• IWR-1-endo: Precision Tool for Advanced Wnt Pathway Dissecti

  2026-05-02

  Explore how IWR-1-endo, a potent Wnt signaling inhibitor, enables rigorous mechanistic studies and next-generation assay development. This article reveals unique insights on Axin-scaffolded complex stabilization and cross-domain research strategies.

• Mifepristone (RU486) in Cancer and Repro Biology: Applied Pr

  2026-05-01

  Mifepristone (RU486) from APExBIO is a high-purity progesterone receptor antagonist enabling reproducible inhibition of tumor growth and modulation of reproductive function. This in-depth guide translates recent mechanistic insights and published workflows into actionable protocols, troubleshooting advice, and comparative advantages for advanced oncology and reproductive biology research.

• Dabigatran Etexilate in Thrombin Inhibition: Protocols & Lab

  2026-05-01

  Dabigatran etexilate empowers researchers to create robust, reproducible models of coagulation and stroke prevention with direct thrombin inhibition. This guide delivers a workflow-centric approach, practical troubleshooting, and evidence-based protocol parameters tailored for translational and mechanistic studies.

• FKBP9 Drives Glioblastoma Malignancy and ER Stress Resistanc

  2026-04-30

  Xu et al. reveal that FKBP9 is overexpressed in glioblastoma and promotes tumor aggressiveness by modulating both p38MAPK and IRE1α-XBP1 signaling pathways. Their study shows that FKBP9 depletion sensitizes glioblastoma cells to endoplasmic reticulum stress inducers, highlighting a potential vulnerability for therapeutic intervention.

• Gramine: A Precision Ferroptosis Inducer in Cancer Biology R

  2026-04-30

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) offers a novel, mechanistically validated tool for dissecting ferroptosis in triple-negative breast cancer via CUL3-mediated MTDH ubiquitination. This article delivers an actionable workflow, optimization strategies, and troubleshooting insights for advanced cancer biology research using Gramine from APExBIO.

• Mifepristone (RU486): Applied Workflows in Cancer & Fertilit

  2026-04-29

  Mifepristone (RU486) stands apart for its dual capabilities in modulating reproductive biology and suppressing diverse tumor types. This guide translates bench research and reference breakthroughs into actionable protocols, troubleshooting insights, and comparative strategies for maximizing APExBIO’s RU486 impact in translational research.

• 6-Thioguanine Inhibits EV71 by Targeting BIRC3-Mediated Auto

  2026-04-29

  You et al. (2025) identify 6-thioguanine as an effective antiviral against Enterovirus 71 (EV71), acting via suppression of BIRC3-mediated autophagy in vitro. This mechanistic insight advances the search for targeted therapies against hand, foot, and mouth disease, and emphasizes the value of antineoplastic agents in antiviral research.

505 records 16/34 page Previous Next First page 上5页 1617181920 下5页 Last page